NYR — Nyrada Share Price
0.000.00%
Last trade - 00:00- AU$54.69m
- AU$48.97m
- AU$3.40m
- 36
- 14
- 78
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.33 | ||
| Price to Tang. Book | 9.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.12% | ||
| Return on Equity | -76.35% | ||
| Operating Margin | -218.97% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.08 | 2.34 | 1.11 | 1.58 | 3.4 | n/a | n/a | 46.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 29th, 2017
- Public Since
- January 16th, 2020
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 210,333,705
- Address
- Suite 2, Level 3,, 828 Pacific Highway, GORDON, 2072
- Web
- https://www.nyrada.com/site/content/
- Phone
- +61 294983390
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for NYR
Similar to NYR
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Nyrada share price?
As of Today at 22:23 UTC, shares in Nyrada are trading at AU$0.26. This share price information is delayed by 15 minutes.
How has the Nyrada share price performed this year?
Shares in Nyrada last closed at AU$0.26 and the price had moved by +377.06% over the past 365 days. In terms of relative price strength the Nyrada share price has outperformed the ASX All Ordinaries Index by +326.51% over the past year.
What are the analyst and broker recommendations for Nyrada?
There is no consensus recommendation for this security.
Find out moreWhat is the Nyrada dividend yield?
Nyrada does not currently pay a dividend.
Does Nyrada pay a dividend?
Nyrada does not currently pay a dividend.
When does Nyrada next pay dividends?
Nyrada does not currently pay a dividend.
How do I buy Nyrada shares?
To buy shares in Nyrada you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nyrada?
As of the previous close price of AU$0.26, shares in Nyrada had a market capitalisation of AU$54.69m.
Where are Nyrada shares listed?
Here are the trading details for Nyrada:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NYR
What kind of share is Nyrada?
Based on an overall assessment of its quality, value and momentum Nyrada is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nyrada share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Nyrada share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nyrada. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +116.82%.
As of the last closing price of AU$0.26, shares in Nyrada were trading +69.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nyrada PE Ratio?
The Nyrada PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nyrada?
We do not have data on Nyrada's directors